FRX Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cispl…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views Fennec Pharmaceuticals is back in focus after analysts lifted their fair value estimate from US$15.33 to US$17.67 per share, pointing to a higher assessed equity value for the stock. Recent commentary links this change to stronger than expected PEDMARK revenue, broader use across several tumor types, and updated views on operating leverage that are feeding into refreshed models. As you read on, you will see how this evolving narrative could shape the way you track Fennec Pharmaceuticals from... | ||
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ... Fennec Pharmaceuticals Inc (FENC) reports a 78% surge in Q2 2026 net product sales to $17.1 million, achieving record EBITDA and positive EPS amid aggressive commercial expansion. | ||
 Adherex Technologies Q2 Earnings Call Highlights Adherex Technologies (NASDAQ:FENC), operating as Fennec Pharmaceuticals, reported second-quarter 2026 net product sales of $17.1 million, up approximately 78% from $9.7 million in the prior-year period, as demand for its PEDMARK therapy continued to rise. Chief Executive Officer Jeff Hackman said t | ||
 Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates Fennec Pharmaceuticals Inc. (NASDAQ:FENC) shares jumped 7. | ||